Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) Equity Ratio (2024 - 2025)

Xilio Therapeutics' Equity Ratio history spans 2 years, with the latest figure at 0.06 for Q3 2025.

  • For Q3 2025, Equity Ratio fell 121.55% year-over-year to 0.06; the TTM value through Sep 2025 reached 0.06, down 121.55%, while the annual FY2024 figure was 0.25, N/A changed from the prior year.
  • Equity Ratio for Q3 2025 was 0.06 at Xilio Therapeutics, down from 0.05 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.37 in Q2 2024 and bottomed at 0.06 in Q3 2025.